白雲山(00874.HK)將“大南藥”研發平台建設項目作延期調整
格隆匯12月11日丨白雲山(00874.HK)公佈,公司根據目前募集資金投資項目的實際情況和需要,經審慎評估,將“大南藥”研發平台建設項目作延期調整,調整後的該項目達到預定可使用狀態的日期為2022年12月31日。
“大南藥”研發平台建設項目包括資產投入及研發投入兩部分。項目的建設內容主要包括科研開發功能區、創新藥物研發中心、藥物製劑研發中心、實驗動物研發中心、綜合辦公區;項目的研發方向主要包括中藥、化學藥、生物製劑、醫療器械和體外試劑診斷、大健康產品、共性技術和關鍵技術等。“大南藥”研發平台建設項目原計劃實施完成時間為2019年12月31日。經研究,公司對“大南藥”研發平台建設項目實施完成時間延期。
目前,廣州白雲山醫藥集團股份有限公司白雲山製藥總廠、廣州白雲山醫藥集團股份有限公司白雲山化學藥廠、廣州白雲山漢方現代藥業有限公司三家企業正在進行的研發項目超40項,相關研發工作正在積極推進當中,募集資金亦將按研發進度撥付。同時,公司亦積極推進其他新增實施主體研發項目的篩選與審批工作,進一步加速募集資金的投入使用。
未來,公司將集中更多的科技資源用於創新藥等重大項目的研發,同時,為加速募集資金投資項目的完成,公司可能會進一步擴大實施主體,充分發揮各子/分公司的研發優勢及資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.